About: Schizophrenia is Associated With an Aberrant Immune Response to Epstein

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Schizophrenia is Associated With an Aberrant Immune Response to Epstein–Barr Virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Schizophrenia is Associated With an Aberrant Immune Response to Epstein–Barr Virus
Creator	Dickerson, Faith Yolken, Robert Khushalani, Sunil Origoni, Andrea Stallings, Cassie Ford, Glen Genovese, Giulio Jones-Brando, Lorraine Katsafanas, Emily O'dushlaine, Colm Sweeney, Kevin
source	PMC
abstract	BACKGROUND: Epstein–Barr virus (EBV) is a highly prevalent human herpesvirus capable of infecting the central nervous system and establishing persistent infection. METHODS: We employed solid phase immunoassay techniques to measure immunoglobulin G (IgG) class antibodies to EBV virions and defined proteins in 432 individuals with schizophrenia and 311 individuals without a history of a psychiatric disorder. Western blot testing was performed to document reactivity to specific EBV proteins. Polygenic risk for schizophrenia was calculated from genome sequencing arrays. Levels of antibodies between the groups were compared by multivariate analyses incorporating clinical, genetic, and demographic measures. RESULTS: Individuals with schizophrenia had marked elevations in the levels of antibodies to EBV virions as compared to the control population. Further analyses indicated increased levels of reactivity to EBV-viral capsid antibody (VCA) but not to EBV nuclear antigen-1 (EBNA-1) or to other human herpesviruses. Western blot analysis confirmed increased reactivity to VCA proteins in the group of individuals with schizophrenia and documented a lack of increased levels of antibodies to EBNA-1. Genetic analyses indicated an additive effect of increased levels of antibodies to EBV virions and genetic susceptibility to schizophrenia, with individuals with elevated levels of both type of markers having a greater than 8.5-fold odds of a schizophrenia diagnosis. CONCLUSIONS: Individuals with schizophrenia have increased levels of antibodies to some but not all EBV proteins indicating an aberrant response to EBV infection. This aberrant response may contribute to the immunopathology of schizophrenia and related disorders.
has issue date	2018-11-20(xsd:dateTime)
bibo:doi	10.1093/schbul/sby164
bibo:pmid	30462333
has license	no-cc
sha1sum (hex)	6d1e0bb8a0e112cde902fbbe768c61526ad6eb04
schema:url	https://doi.org/10.1093/schbul/sby164
resource representing a document's title	Schizophrenia is Associated With an Aberrant Immune Response to Epstein–Barr Virus
has PubMed Central identifier	PMC6737467
has PubMed identifier	30462333
schema:publication	Schizophr Bull
resource representing a document's body	covid:6d1e0bb8a0e112cde902fbbe768c61526ad6eb04#body_text
is schema:about of	named entity 'analyses' named entity 'performed' named entity 'EBV' named entity 'genetic' named entity 'This' named entity 'control' named entity 'Immune' named entity 'NUCLEAR ANTIGEN' named entity 'CLINICAL' named entity 'PSYCHIATRIC DISORDER' named entity 'OTHER HUMAN HERPESVIRUSES' named entity 'GENETIC SUSCEPTIBILITY' named entity 'WESTERN BLOT ANALYSIS' named entity 'RELATED' named entity 'ADDITIVE' named entity 'MEASURES' named entity 'SOLID PHASE' named entity 'LACK' named entity 'CONCLUSIONS' named entity 'BUT' named entity 'EFFECT' named entity 'CONTRIBUTE ' named entity 'SPECIFIC' named entity 'VIRIONS' named entity 'EMPLOYED' named entity 'GROUP OF INDIVIDUALS' named entity 'EBV' covid:arg/6d1e0bb8a0e112cde902fbbe768c61526ad6eb04 named entity 'ASSOCIATED WITH' named entity 'SCHIZOPHRENIA' named entity 'WESTERN BLOT' named entity 'GENOME SEQUENCING' named entity 'EPSTEIN-BARR VIRUS' named entity 'GENETIC' named entity 'ABERRANT' named entity 'DEMOGRAPHIC' named entity 'REACTIVITY' named entity 'INDICATING' named entity 'CONTROL POPULATION' named entity 'IMMUNOASSAY' named entity 'ELEVATED' named entity 'ELEVATIONS' named entity 'TECHNIQUES' named entity 'GROUPS' named entity 'INDICATED' named entity 'DOCUMENTED' named entity 'CALCULATED' named entity 'IMMUNE RESPONSE' named entity 'ANTIBODIES' named entity 'PROTEINS' named entity 'INDIVIDUALS' named entity 'ABERRANT' named entity 'RESPONSE TO' named entity 'DOCUMENT ' named entity '311' named entity 'DIAGNOSIS' named entity 'INCREASED' named entity 'RISK' named entity 'RESPONSE TO' named entity 'IMMUNOPATHOLOGY' named entity 'GREATER THAN' named entity 'HAVE' named entity 'LEVELS' named entity 'ANTIBODY' named entity 'EBNA-1' named entity '8.5' named entity 'TESTING WAS PERFORMED' named entity 'MARKED' named entity 'RESPONSE' named entity 'FOLD' named entity 'COMPARED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software